Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers. We analyze key trends and...
Ligand Pharmaceuticals ([[LGND]] +1.3%) announces that it has sold its Vernalis research operations and internal programs to HitGen Inc. for $25M in cash.Ligand to retain economic rights on completed collaboration licenses as well as a share of the economic rights on current research collabor...
Consideration includes $25 million cash payment plus Ligand retains economics on completed partnerships and share of economics on current collaborations Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operati...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20 th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: John Higgins, Chief Executive Officer Matt F...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...
Ligand Pharmaceuticals ([[LGND]] +5.0%) expects Captisol material sales of ~$200M in 2021 compared to its 2020 full-year expectation of $90M.The company said “recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operat...
Recent partner contracts and manufacturing investments have Captisol business operating at record high levels Continued clinical progress of Captisol-enabled drugs affirms the value of the proprietary technology Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) anno...
Ligand inks deal to acquire Taurus and xCella Biosciences Ligand Pharmaceuticals Inc. ( LGND ) reported that it has inked a deal to acquire two companies, xCella Biosciences Inc. and Taurus Biosciences. Both these companies are privately held and are expected to boost Ligand’s Omn...
Ligand Pharmaceuticals (NASDAQ: LGND ) acquired two privately held companies that strengthen and complement its OmniAb ® technology platform. More news on: Ligand Pharmaceuticals Incorporated, Merger & acquisition news, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...